Plant ID: NPO16741
Plant Latin Name: Codonopsis pilosula
Taxonomy Genus: Codonopsis
Taxonomy Family: Campanulaceae
NCBI TaxonomyDB:
86864
Plant-of-the-World-Online:
n.a.
Thailand; South Korea; China
ADORA3; ADORA2A; ADORA1; HCAR2; | |
NPSR1; | |
RECQL; TDP1; P4HB; ADK; GLO1; ALOX12; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
ACHE; | |
TOP2A; | |
AXL; MET; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
CA2; CA12; CA7; CA4; | |
TYR; | |
KDM4E; | |
AHR; | |
FUT7; | |
LMNA; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.116E-08 | 5.120E-05 | CA12, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.379E-08 | 7.358E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.357E-07 | 1.641E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.863E-07 | 2.710E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 6.851E-07 | 5.144E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 8.719E-07 | 6.023E-04 | ADORA1, ADORA2A, ALOX12, AURKB, AXL, CDK1, GLO1, IGF1R, KDR, LMNA, PIM1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.851E-07 | 6.023E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.773E-07 | 6.449E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.016E-06 | 1.081E-03 | CA12, CA2, CA4, CA7 |
BP | GO:0065007; biological regulation | GO:0042592; homeostatic process | 2.035E-06 | 1.081E-03 | ADORA1, ALOX12, APEX1, AXL, CA12, CA2, CA7, FLT3, MET, NOX4, NPSR1, P4HB, POLB |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 2.319E-06 | 1.148E-03 | ADORA2A, CA2, CA7 |
BP | GO:0040011; locomotion | GO:0030334; regulation of cell migration | 2.862E-06 | 1.355E-03 | ADORA1, ADORA3, ALOX12, APEX1, CYP1B1, IGF1R, KDR, LMNA, MET, NOX4 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.103E-06 | 1.751E-03 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 4.181E-06 | 1.751E-03 | APEX1, POLB |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.454E-06 | 2.382E-03 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
BP | GO:0032502; developmental process | GO:0007568; aging | 7.489E-06 | 2.570E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 7.554E-06 | 2.570E-03 | APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.066E-05 | 3.317E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.253E-05 | 3.637E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.253E-05 | 3.637E-03 | CYP1A1, CYP3A4 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.253E-05 | 3.637E-03 | ADORA1, ADORA2A |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.416E-05 | 4.056E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 1.519E-05 | 4.296E-03 | ADORA1, ADORA2A, ADORA3, AHR, ALOX12, CDK1, CYP1B1, FLT3, IGF1R, KDR, LMNA, NOX4, PIM1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.907E-05 | 5.003E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.502E-05 | 5.987E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.502E-05 | 5.987E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 3.927E-05 | 8.467E-03 | AXL, FLT3, IGF1R, KDR, MET |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.165E-05 | 8.637E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 5.040E-05 | 9.829E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.047E-07 | 4.607E-06 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.203E-08 | 2.819E-06 | CA12, CA2, CA4, CA7 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.956E-06 | 8.669E-05 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.351E-05 | 2.973E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.144E-05 | 3.773E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 6.956E-05 | 1.020E-03 | CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 6.216E-04 | 6.838E-03 | FUT7, HSD17B2, CYP1A2, CYP1A1, ADK, ALOX12, CYP3A4, TYR, HSD17B10 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.971E-04 | 3.734E-03 | CYP1A2, CYP1A1, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 8.172E-04 | 7.990E-03 | ADORA2A, KDR, MET, IGF1R |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 9.609E-04 | 8.456E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; ADORA2A; ADK; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
NA: NA | Edema | NA | CA2; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; HCAR2; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; ACHE; ADORA3; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HCAR2; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
NA: NA | HIV infections | NA | AHR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; HCAR2; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; HCAR2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |